Searchable abstracts of presentations at key conferences in endocrinology

ea0090ep617 | Endocrine-related Cancer | ECE2023

Molecular predictors of response to the therapy with mitotane in adrenocortical cancer

Porubayeva Erika , Selivanova Lilia

Background: Adrenocortical cancer (ACC) therapy is characterized by insufficient effectiveness. Currently, mitotane, an adrenolytic drug, is the only drug approved for treatment of ACC and is used in the adjuvant setting and in case of metastatic or advanced disease. However, the administration of mitotane to certain groups of patients remains controversial due to the low response rates, high toxicity and limited data on the benefit of treatment. Expression levels of the large...

ea0067gp18 | Poster Presentations | EYES2019

Clinical case of adrenocortical carcinoma: rapid metastatic progression after mitotane discontinuation

Beltsevich Dmitry , Rosyakova Anna , Selivanova Lilia , Tarbaeva Natalia

Background: Adrenocortical carcinoma (ACC) is a rare malignant tumor with a poor prognosis. The only curative therapy is complete surgery (R0). A 5-year local recurrence and distant metastasis rate after R0 is 80–85%. Mitotane is widely used as an adjuvant treatment in patients with a high risk of recurrence. According to the most studies, it can delay and possibly prevent a recurrence of the disease in 35–50%. However, its efficacy is controversial, as well as the o...

ea0070aep41 | Adrenal and Cardiovascular Endocrinology | ECE2020

Somatostatin receptors 2A and 5 expression in adrenocortical cancer

Roslyakova Anna , Selivanova Lilia , Tarasova Arina , Beltsevich Dmitry

Introduction: Adrenocortical carcinoma (ACC) is a rare malignant tumor with heterogeneous prognosis. The median overall survival of all ACC patients is about 3-4 years. Complete surgical resection provides the only cure [Fassnacht M, et al., 2018]. In cases of advanced ACC, therapeutic options are limited. No effective second-line therapies are recommended for patients with disease progression to EDP chemotherapy scheme and Mitotane. It is essential to study alternative drugs,...

ea0099p180 | Late-Breaking | ECE2024

Immunohistochemistry in the differential diagnosis of atypical tumor and parathyroid carcinoma

Kim Ekaterina , Lavreniuk Anastasiia , Elfimova Alina , Eremkina Anna , Selivanova Lilia , Salimkhanov Rustam , Mokrysheva Natalia

Background: Atypical parathyroid tumor (APT) generally has a better prognosis compared to parathyroid carcinoma (PC). The differential diagnosis of APT and PC is crucial for further management. Diagnosis of both is based on morphological examination but sometimes can be challenging. In such cases immunohistochemistry (IHC) should be used.Objective: To estimate the utility of IHC in the differential diagnosis of APT and PC.Materials...

ea0099ep550 | Thyroid | ECE2024

Clinical case of a combination of giant prolactinoma and medullary thyroid cancer

Perepelova Margarita , Przhiyalkovskaya Elena , Pigarova Ekaterina , Nikiforovich Petr , Selivanova Lilia , Roslyakova Anna , Shutova Aleksandra , Dzeranova Larisa

Background: The combination of various endocrine tumours is presented both as hereditary syndromes and sporadic forms. Medullary thyroid cancer and prolactinoma are neuroendocrine tumours, the presence of these two pathologies simultaneously has not been previously described in the literature.Objective: To present a clinical case of a patient with giant prolactinoma and medullary thyroid cancer.Materials and Methods: To describe th...

ea0099p328 | Pituitary and Neuroendocrinology | ECE2024

Cytological, immunological and radiological predictors of the efficacy of first-generation somatostatin receptor ligands (fg-SRLs) in patients with acromegaly

Pronin Evgeny , Antsiferov Mikhail , Petraikin Alexey , Pronin Vyacheslav , Alekseeva Tatiana , Lapshina Anastasia , Selivanova Lilia , Khoruzhaya Anna , Tamaeva Safi

Taking into account heterogeneity of somatotrophic tumors (STs), intragroup differential diagnostics is of practical importance, since it allows to predict scenario of acromegaly clinical course, as well as the efficacy of secondary drug therapy (DT).The aim of this study was to determine prognostic power of cytological, immunological&radiological predictors of sensitivity/resistance to fg-SRLs in patients with pure somatotropinomas.Materials and Met...